A citation-based method for searching scientific literature

Nikita Katila, Sunil Bhurtel, Sina Shadfar, Sunil Srivastav, Sabita Neupane, Uttam Ojha, Gil-Saeng Jeong, Dong-Young Choi. Neuropharmacology 2017
Times Cited: 85







List of co-cited articles
1277 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice.
S P Patil, P D Jain, P J Ghumatkar, R Tambe, S Sathaye. Neuroscience 2014
160
35

Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Mark L Wahlqvist, Meei-Shyuan Lee, Chih-Cheng Hsu, Shao-Yuan Chuang, Jiunn-Tay Lee, Hsin-Ni Tsai. Parkinsonism Relat Disord 2012
149
31

The Therapeutic Potential of Metformin in Neurodegenerative Diseases.
Carola Rotermund, Gerrit Machetanz, Julia C Fitzgerald. Front Endocrinol (Lausanne) 2018
138
25

Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation.
B I Pérez-Revuelta, M M Hettich, A Ciociaro, C Rotermund, P J Kahle, S Krauss, D A Di Monte. Cell Death Dis 2014
86
24

Metformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons.
Jacqueline A Bayliss, Moyra B Lemus, Vanessa V Santos, Minh Deo, Jeffrey S Davies, Bruce E Kemp, John D Elsworth, Zane B Andrews. PLoS One 2016
40
47

Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system.
Afrah A K Ismaiel, Ana M Espinosa-Oliva, Martiniano Santiago, Albert García-Quintanilla, María J Oliva-Martín, Antonio J Herrera, José L Venero, Rocío M de Pablos. Toxicol Appl Pharmacol 2016
41
43

Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
Yi-Chun Kuan, Kuang-Wei Huang, Cheng-Li Lin, Chaur-Jong Hu, Chia-Hung Kao. Prog Neuropsychopharmacol Biol Psychiatry 2017
80
21

Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice.
Zhenri Ou, Xuejian Kong, Xiangdong Sun, Xiaosong He, Le Zhang, Zhuo Gong, Jingyi Huang, Biao Xu, Dahong Long, Jianhua Li,[...]. Brain Behav Immun 2018
164
20

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
354
16

Type 2 diabetes and the risk of Parkinson's disease.
Gang Hu, Pekka Jousilahti, Siamak Bidel, Riitta Antikainen, Jaakko Tuomilehto. Diabetes Care 2007
291
16

Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide.
Krzysztof Łabuzek, Dariusz Suchy, Bożena Gabryel, Anna Bielecka, Sebastian Liber, Bogusław Okopień. Pharmacol Rep 2010
237
16

Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling.
Eva Kickstein, Sybille Krauss, Paul Thornhill, Désirée Rutschow, Raphael Zeller, John Sharkey, Ritchie Williamson, Melanie Fuchs, Andrea Köhler, Hartmut Glossmann,[...]. Proc Natl Acad Sci U S A 2010
294
16

Role of AMP-activated protein kinase in mechanism of metformin action.
G Zhou, R Myers, Y Li, Y Chen, X Shen, J Fenyk-Melody, M Wu, J Ventre, T Doebber, N Fujii,[...]. J Clin Invest 2001
16

Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies.
Xuejing Yue, Hehua Li, Haiqing Yan, Ping Zhang, Li Chang, Tong Li. Medicine (Baltimore) 2016
80
16

Metformin improves healthspan and lifespan in mice.
Alejandro Martin-Montalvo, Evi M Mercken, Sarah J Mitchell, Hector H Palacios, Patricia L Mote, Morten Scheibye-Knudsen, Ana P Gomes, Theresa M Ward, Robin K Minor, Marie-José Blouin,[...]. Nat Commun 2013
777
15

Glitazone use associated with reduced risk of Parkinson's disease.
Brage Brakedal, Irene Flønes, Simone F Reiter, Øivind Torkildsen, Christian Dölle, Jörg Assmus, Kristoffer Haugarvoll, Charalampos Tzoulis. Mov Disord 2017
64
18

Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection.
Hojin Kang, Rin Khang, Sangwoo Ham, Ga Ram Jeong, Hyojung Kim, Minkyung Jo, Byoung Dae Lee, Yun Il Lee, Areum Jo, ChiHu Park,[...]. Oncotarget 2017
37
32

Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.
Julia C Fitzgerald, Alexander Zimprich, Daniel A Carvajal Berrio, Kevin M Schindler, Brigitte Maurer, Claudia Schulte, Christine Bus, Anne-Kathrin Hauser, Manuela Kübler, Rahel Lewin,[...]. Brain 2017
62
19

Divergent Effects of Metformin on an Inflammatory Model of Parkinson's Disease.
Khadija Tayara, Ana M Espinosa-Oliva, Irene García-Domínguez, Afrah Abdul Ismaiel, Antonio Boza-Serrano, Tomas Deierborg, Alberto Machado, Antonio J Herrera, José L Venero, Rocío M de Pablos. Front Cell Neurosci 2018
27
44

Parkinson disease.
Werner Poewe, Klaus Seppi, Caroline M Tanner, Glenda M Halliday, Patrik Brundin, Jens Volkmann, Anette-Eleonore Schrag, Anthony E Lang. Nat Rev Dis Primers 2017
12

Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis.
Emanuele Cereda, Michela Barichella, Carlo Pedrolli, Catherine Klersy, Erica Cassani, Riccardo Caccialanza, Gianni Pezzoli. Diabetes Care 2011
138
12

Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.
Yaomin Chen, Kun Zhou, Ruishan Wang, Yun Liu, Young-Don Kwak, Tao Ma, Robert C Thompson, Yongbo Zhao, Layton Smith, Laura Gasparini,[...]. Proc Natl Acad Sci U S A 2009
296
12

Parkinson's disease.
Lorraine V Kalia, Anthony E Lang. Lancet 2015
12

Diabetes mellitus and Parkinson disease.
Gennaro Pagano, Sotirios Polychronis, Heather Wilson, Beniamino Giordano, Nicola Ferrara, Flavia Niccolini, Marios Politis. Neurology 2018
95
12

Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk.
Yam Nath Paudel, Efthalia Angelopoulou, Christina Piperi, Mohd Farooq Shaikh, Iekhsan Othman. Pharmacol Res 2020
34
32

Diabetes and risk of Parkinson's disease.
Qun Xu, Yikyung Park, Xuemei Huang, Albert Hollenbeck, Aaron Blair, Arthur Schatzkin, Honglei Chen. Diabetes Care 2011
167
11

Metformin: from mechanisms of action to therapies.
Marc Foretz, Bruno Guigas, Luc Bertrand, Michael Pollak, Benoit Viollet. Cell Metab 2014
709
11

Diabetes and the risk of developing Parkinson's disease in Denmark.
Eva Schernhammer, Johnni Hansen, Kathrine Rugbjerg, Lene Wermuth, Beate Ritz. Diabetes Care 2011
120
11


Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.
M Y El-Mir, V Nogueira, E Fontaine, N Avéret, M Rigoulet, X Leverve. J Biol Chem 2000
985
11


Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
286
11

Metformin as a Tool to Target Aging.
Nir Barzilai, Jill P Crandall, Stephen B Kritchevsky, Mark A Espeland. Cell Metab 2016
493
10

The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro.
Marija Dulovic, Maja Jovanovic, Maria Xilouri, Leonidas Stefanis, Ljubica Harhaji-Trajkovic, Tamara Kravic-Stevovic, Verica Paunovic, Mustafa T Ardah, Omar M A El-Agnaf, Vladimir Kostic,[...]. Neurobiol Dis 2014
82
10

Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study.
Aaron M Koenig, Dawn Mechanic-Hamilton, Sharon X Xie, Martha F Combs, Anne R Cappola, Long Xie, John A Detre, David A Wolk, Steven E Arnold. Alzheimer Dis Assoc Disord 2017
157
10

Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study.
Patrick Imfeld, Michael Bodmer, Susan S Jick, Christoph R Meier. J Am Geriatr Soc 2012
234
10

Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson's Disease.
Daniel W Curry, Bernardo Stutz, Zane B Andrews, John D Elsworth. J Parkinsons Dis 2018
56
16

Increased risk of cognitive impairment in patients with diabetes is associated with metformin.
Eileen M Moore, Alastair G Mander, David Ames, Mark A Kotowicz, Ross P Carne, Henry Brodaty, Michael Woodward, Karyn Boundy, Kathryn A Ellis, Ashley I Bush,[...]. Diabetes Care 2013
223
10


Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies.
Hugo Vicente Miranda, Éva M Szego, Luís M A Oliveira, Carlo Breda, Ekrem Darendelioglu, Rita M de Oliveira, Diana G Ferreira, Marcos A Gomes, Ruth Rott, Márcia Oliveira,[...]. Brain 2017
101
9

Clinical features of Parkinson disease when onset of diabetes came first: A case-control study.
E Cereda, M Barichella, E Cassani, R Caccialanza, G Pezzoli. Neurology 2012
92
9

Alpha-synuclein in Lewy bodies.
M G Spillantini, M L Schmidt, V M Lee, J Q Trojanowski, R Jakes, M Goedert. Nature 1997
9

Mitochondrial dysfunction in Parkinson's disease.
Anindita Bose, M Flint Beal. J Neurochem 2016
387
9

Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction.
Ming-Chang Chiang, Yi-Chuan Cheng, Shiang-Jiuun Chen, Chia-Hui Yen, Rong-Nan Huang. Exp Cell Res 2016
57
14

Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice.
Jiejie Li, Jiao Deng, Wenli Sheng, Zhiyi Zuo. Pharmacol Biochem Behav 2012
178
9

Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.
Magdalena Markowicz-Piasecka, Joanna Sikora, Aleksandra Szydłowska, Agata Skupień, Elżbieta Mikiciuk-Olasik, Kristiina M Huttunen. Pharm Res 2017
136
9

Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation.
Jing Wang, Denis Gallagher, Loren M DeVito, Gonzalo I Cancino, David Tsui, Ling He, Gordon M Keller, Paul W Frankland, David R Kaplan, Freda D Miller. Cell Stem Cell 2012
301
9

Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Young-Kyoung Ryu, Hye-Yeon Park, Jun Go, Dong-Hee Choi, Yong-Hoon Kim, Jung Hwan Hwang, Jung-Ran Noh, Tae Geol Lee, Chul-Ho Lee, Kyoung-Shim Kim. Mol Neurobiol 2018
22
36

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
166
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.